Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Fastly Inc (FSLY) vs Pfizer Inc (PFE) Price & Performance

Fastly IncTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

Fastly Inc vs Pfizer Inc — how do they compare? Fastly Inc trades at $20.38 (market cap $3.13B), while Pfizer Inc trades at $25.31 (market cap $141.46B). The key difference: Pfizer Inc is far larger — about 45.2× Fastly Inc's market cap, and Pfizer Inc pays a 6.93% dividend while Fastly Inc pays none. Which is the better fit depends on your goals.

FSLYPFE
Market Cap
$3.13B$141.46B
Sector
TechnologyHealth
52-Week High
$33.50$28.56
52-Week Low
$6.36$23.29
Enterprise Value
$3.20B$192.12B
Volume
29,869,932
Dividend Yield
6.93%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Fastly Inc

Fastly (FSLY) trades at $20.90, up 4.34% today, showing strong momentum after three consecutive quarterly earnings beats. The stock maintains a bullish technical signal with positive moving averages and trades near key resistance at $21-$22. Revenue growth continues at 20% year-over-year, though the company remains unprofitable with a -15.79% net margin. Recent news highlights strategic partnerships in edge computing and AI infrastructure development.

Despite consistent revenue growth and improving margins, Fastly faces profitability challenges with negative ROE and cash flow volatility. Analyst consensus is mixed with 29% buy ratings but a $24.25 price target suggesting 16% upside. Key risks include competitive pressure from larger cloud providers and the company's ability to achieve sustainable profitability amid heavy infrastructure investments.

Pfizer Inc

Pfizer (PFE) trades at $24.25, down 0.94% on the day, with a bearish technical signal from moving averages. The company reported $62.58B in 2025 revenue and a net income margin of 11.83%, with recent quarterly earnings consistently beating expectations. A dividend of $0.43 per share is scheduled for payment on September 1, 2026. The stock's valuation includes a P/E of 18.51 and P/S of 2.19, while analyst consensus price target is $28.25.

Pfizer presents a mixed outlook with stable profitability and a strong dividend, but faces headwinds from patent expirations and competitive pressures. The stock offers value at current levels relative to analyst targets, though technical weakness and revenue declines from peak COVID-era sales pose near-term risks for investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Fastly Inc

Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.

Read more on FSLY

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE